Results of very recent animal studies expand this diversity by demonstrating CD36 involvement in an AD-associated blood brain barrier disruption70, and in an interaction with the nerve growth regulator1 (NEGR1)71, i.e., in AD-related mechanisms distinct from those active in the amyloid/tau pathways and/or the amyloid-β phagocytosis by microglia. The gene discussed is CD36; the disease is Alzheimer disease.